MBRX is trading 5% down at $2.51 in pre-market, extending a multi-day slide following disappointing interim cancer trial data and a sizable Q1 2026 earnings miss.
- The stock dropped sharply after its trial data fell short of statistical significance, reinforcing concerns about Moleculin’s funding needs and trial trajectory.
- A significant EPS miss has overshadowed earlier positive signals from the MIRACLE study, intensifying investor anxiety over the company's financial runway.